Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1562474

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1562474

Contrast Media Market Size, Share, Growth Analysis, By Type, By Form, By Modality, By Route of Administration, By Region - Industry Forecast 2024-2031

PUBLISHED:
PAGES: 260 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5300
PDF & Excel (Multiple User License)
USD 6200
PDF & Excel (Enterprise License)
USD 7100

Add to Cart

Global Contrast Media Market size was valued at USD 6.10 billion in 2022 and is poised to grow from USD 6.55 billion in 2023 to USD 11.60 billion by 2031, growing at a CAGR of 7.4% during the forecast period (2024-2031).

The increasing prevalence of complex comorbidities and chronic illnesses is driving the growing use of diagnostic imaging procedures, including ultrasound, X-rays, MRI, and CT scans. For instance, the U.S. FDA approved GE Healthcare's Clariscan, a macrocyclic MRI contrast agent, in November 2019. Such innovations are crucial for determining the need for perioperative scans and interventions, contributing to market expansion. According to the National Health Council, approximately 81 million Americans had multiple chronic conditions in 2019, highlighting the significant prevalence of these diseases. Projections suggest that nearly 157 million Americans will be affected by chronic illnesses in the near future. Chronic diseases are particularly prevalent among older adults, with about 80% of individuals aged 65 and older having at least one chronic illness, and nearly 70% of Medicare recipients managing multiple conditions, according to the National Council on Aging. By 2034, it is anticipated that approximately 77 million Americans will be 65 or older. Additionally, heart failure, a major cause of death in the U.S., is becoming increasingly common. The American Heart Association reports that around 659,000 Americans died from cardiovascular disorders in 2019, and the number of heart disease cases is expected to rise by 46% by 2031. These trends are expected to drive the demand for contrast media in the global market over the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Contrast Media market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contrast Media Market Segmental Analysis

Global Contrast Media Market is segmented by Type, Form, Modality, Route of Administration, Indication, Application, End User, and region. Based on Type, the market is segmented into Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, and Barium-based Contrast Media. Based on Form, the market is segmented into Liquid Contrast Media, Powder Contrast Media, and Other Forms. Based on Modality, the market is segmented into X-RAY, CT, MRI, and Ultrasound. Based on Route of Administration, the market is segmented into Intravascular Route [Intravenous (IV) route, Intra-arterial (IA) route], Oral Route, Rectal Route, and Other Routes. Based on Indication, the market is segmented into Cardiovascular Disease, Cancer, Gastrointestinal Disorders, Musculoskeletal Disorders, Neurological Disorders, and Nephrological Disorders. Based on Application, the market is segmented into Radiology, Interventional Radiology, and Interventional Cardiology. Based on End User, the market is segmented into Hospitals, Clinics, And Ambulatory Surgery Centers, and Diagnostic Imaging Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Contrast Media Market

The global rise in chronic illnesses has led to a substantial increase in the demand for diagnostic imaging procedures and, by extension, contrast media. To address this growing need and to gain approval for new indications, manufacturers of contrast media have been heavily investing in research and development. This investment aims to bring innovative products to the market and enhance their existing offerings. For example, the US FDA approved a new 20-vial pack design of the ultrasound contrast agent Lumason for use by Bracco. This approval reflects the industry's efforts to meet the increasing demand for advanced imaging solutions and to provide healthcare professionals with more effective tools for diagnosing and managing chronic conditions.

Restraints in the Global Contrast Media Market

Contrast agents are widely utilized in various diagnostic techniques, such as MRI and CT scans, due to their ability to enhance imaging clarity. However, the market's growth may be somewhat limited by the potential for adverse effects and allergic reactions associated with their use. Although these negative reactions can vary from mild to severe, it is important to note that severe and major allergic responses are relatively rare.

Market Trends of the Global Contrast Media Market

Iodinated contrast medium is a type of intravenous radiocontrast used to enhance the visibility of vascular systems and organs during radiographic procedures. This contrast medium has been instrumental in detecting conditions such as cancer by improving imaging clarity. The current iodinated contrast media are developed from chemically modified tri-iodinated benzene rings. The effectiveness of iodinated contrast media in attenuating X-rays is influenced by the amount of iodine present in the tissue being imaged, with this attenuation being inversely related to the X-ray energy used. Consequently, the selection and quantity of contrast media needed for specific imaging tasks are based on the desired imaging quality.

Product Code: SQMIG35B2070

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • Trade Analysis
  • Supply chain Analysis
  • Case study Analysis
  • Patent Analysis
  • Customer & Buying Criteria Analysis
  • Regulatory Landscape
  • Innovation Matrix
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Contrast Media Market by Type

  • Market Overview
  • Iodinated Contrast Media
  • Gadolinium-based Contrast Media
  • Microbubble Contrast Media
  • Barium-based Contrast Media

Contrast Media Market by Form

  • Market Overview
  • Liquid Contrast Media
  • Powder Contrast Media
  • Other Forms

Contrast Media Market by Modality

  • Market Overview
  • X-RAY
  • CT
  • MRI
  • Ultrasound

Contrast Media Market by Route of Administration

  • Market Overview
  • Intravascular Route
    • Intravenous (IV) route
    • Intra-arterial (IA) route
  • Oral Route
  • Rectal Route
  • Other Routes

Contrast Media Market by Indication

  • Market Overview
  • Cardiovascular Disease
  • Cancer
  • Gastrointestinal Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Nephrological Disorders

Contrast Media Market by Application

  • Market Overview
  • Radiology
  • Interventional Radiology
  • Interventional Cardiology

Contrast Media Market by End User

  • Market Overview
  • Hospitals, Clinics, And Ambulatory Surgery Centers
  • Diagnostic Imaging Centers

Contrast Media Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • GE Healthcare (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bracco Imaging SpA (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Guerbet (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lantheus Medical Imaging (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Unijules Life Sciences Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • J.B. Chemicals & Pharmaceuticals Limited (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Taejoon Pharm Co., Ltd. (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Jodas Expoim (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Imax Diagnostic Imaging Limited (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Yangtze River Pharmaceutical Group (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Livealth Biopharma (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Beijing Beilu Pharmaceutical Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Unispire Biopharma Private Limited (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Arco Lifesciences (I) Pvt. Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Stanex Drugs & Chemicals Pvt. Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Rege Imaging & Cine Films Private Limited (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • K Diam Exim (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Onko Ilac San. ve Tic. A.S. (Turkey)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fresenius Kabi (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biem Ilac San. ve Tic. A.S. (Turkey)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Advacare Pharma (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!